Circulation:IL-6信号遗传缺陷可可降低克隆造血变异个体的心血管风险

2020-01-28 QQY MedSci原创

不确定潜能克隆性造血(Clonal hematopoiesis of indeterminate potential,CHIP)是指造血干细胞克隆扩增导致产生获得性白血病突变,如DNMT3A或TET2。在人类中,CHIP与心肌梗死相关。在小鼠中,CHIP可恶化动脉粥样硬化,增加IL-6/IL-1β的表达,引发这样一个推测:IL-6通路拮抗剂或可降低CHIP携带者的心血管疾病(CVD)风险。研究人员

不确定潜能克隆性造血(Clonal hematopoiesis of indeterminate potential,CHIP)是指造血干细胞克隆扩增导致产生获得性白血病突变,如DNMT3A或TET2。在人类中,CHIP与心肌梗死相关。在小鼠中,CHIP可恶化动脉粥样硬化,增加IL-6/IL-1β的表达,引发这样一个推测:IL-6通路拮抗剂或可降低CHIP携带者的心血管疾病(CVD)风险。

研究人员分析了UK生物库中无CVD的35416位个体的外显子序列,来鉴别携带DNMT3A或TET2 CHIP的个体。研究人员以IL6R p.Asp358Ala编码突变作为IL-6抑制的遗传代理,检测了CHIP状态与CVD事件(心肌梗死、冠脉重建、卒中或死亡)之间的相关性,同时评估其是否受IL6R p.Asp358Ala影响。

共筛选出1079位(3.0%)位携带CHIP的个体,其中432位(1.2%)携带大克隆(等位基因频率>10%)。中位随访6.9年期间,CHIP与CVD事件风险增加相关(风险比[HR] 1.27[95% CI 1.04-1.56],P=0.019),携带大CHIP克隆的个体CVD事件风险增加的更显著(HR 1.59[95% CI 1.21-2.09],P<0.001)。IL6R p.Asp358Ala可降低携带大CHIP克隆个体的CVD事件风险(HR 0.46[95% CI 0.29-0.73],P<0.001),但不影响无CHIP个体的。在9951位独立的受试者中,CHIP状态与心肌梗死的相关性也随着IL6R p.Asp358Ala状态而改变。

CHIP与CVD事件风险增加相关。对于大CHIP克隆的携带者,从基因上减弱IL-6信号可以消除这种风险。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-06-06 rgjl
  3. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-02-04 aids221
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-01-30 1478fa69m73暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-01-30 kzlchina
  6. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-01-30 俅侠
  8. [GetPortalCommentsPageByObjectIdResponse(id=2082525, encodeId=0d0920825255f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 29 19:56:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018115, encodeId=2a9d2018115f5, content=<a href='/topic/show?id=6516952018a' target=_blank style='color:#2F92EE;'>#遗传缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95201, encryptionId=6516952018a, topicName=遗传缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Jun 06 17:56:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660210, encodeId=de8d166021072, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Feb 04 17:56:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378708, encodeId=6cf93e8708d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:20:06 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273787, encodeId=7a6b12e37876f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342645, encodeId=4e6e134264552, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494708, encodeId=3dc81494e08df, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575343, encodeId=da9615e534304, content=<a href='/topic/show?id=e53f2892902' target=_blank style='color:#2F92EE;'>#克隆造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28929, encryptionId=e53f2892902, topicName=克隆造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=099216108487, createdName=pyaili, createdTime=Thu Jan 30 06:56:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

相关资讯

AP&T: 血清白细胞介素-6水平升高与肝硬化患者肝性脑病的发生率相关

全身性炎症是肝性脑病发展的驱动力,最近的研究表明,肝硬化患者血清白介素-6(IL-6)血清水平升高与肝性脑病发生相关。本项研究旨在检验IL-6是否是合适的标志物可以用于鉴定有明显肝性脑病高发风险的肝硬化患者。

Blood:树突细胞来源的IL-6失调介导alloSCT后移植物抗宿主病的发生

中心点:DCs是异体移植后IL-6失调的主要来源。IL-6依赖性GVHD受供体T细胞上的IL-6R经典信号驱动,但受反式信号调控。摘要:异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素-6 (IL-6)调节异常。IL-6可以通过多种途径介导作用,包括经典、反式和簇信号。鉴于近年来有多种药物可以抑制这些离散的信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至

J Periodontol: 人牙龈成纤维细胞中rho-激酶抑制剂y-27632通过阻断p38MAPK和 NF-κB通路下调lps诱导的IL-6和IL-8的分泌

牙龈卟啉单胞菌脂多糖(LPS)在慢性牙周炎的发生发展中起着主要的作用。人牙龈成纤维细胞(HGF)与细菌或细菌产物相互作用并引发破坏牙周组织的炎症信号传导通路。 RhoA调节各种细胞类型中细胞因子的产生。本研究旨在探讨Rho激酶抑制剂Y-27632在LPS诱导的核因子κB(NF-κB)和p-38丝裂原活化蛋白激酶(MAPK)活化中的作用,以及HGF中炎性因子的产生。

Neurology:炎症因子与中风

研究认为IL-6与中风的发生风险密切相关

Blood:树突细胞的IL-6失调通过经典信号传导引发移植物抗宿主病

同种异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素6 (IL-6)调节异常。IL-6可通过多种途径介导其作用,包括经典、反式和群集信号。鉴于近年来有多种药物可以抑制这些离散信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至关重要。Wilkinson等人发现受体树突细胞(DC)分泌的IL-6启动了这种细胞因子的系统失调。靶向敲除T细胞中的IL-6受体(IL

J Endod:IL-6在牙髓干细胞成骨和神经分化潜力中的作用

研究显示,感染牙髓中IL-6的浓度明显高于健康牙髓组织。这篇研究的目的是为了评估健康人牙髓干细胞(H-DPSCs)和感染牙髓干细胞(I-DPSCs)中分离出来的间充质干细胞(MSCs)之间的基线差异以及它们与IL-6的相关性,并评估IL-6是否会影响这些细胞的分化潜力。